专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明公开

EP1968631A2 VACCINE 无效
标题翻译：疫苗
公开(公告)号：EP1968631A2
公开(公告)日：2008-09-17
申请号：EP06841492.9
申请日：2006-12-20
申请人： GlaxoSmithKline Biologicals S.A.
发明人： BIEMANS, Ralph Leon , GARCON, Nathalie Marie-Josephe , HERMAND, Philippe Vincent , POOLMAN, Jan , VAN MECHELEN, Marcelle Paulette
IPC分类号： A61K39/09
CPC分类号： A61K39/385 , A61K39/092 , A61K47/6415 , A61K47/646 , A61K2039/545 , A61K2039/55 , A61K2039/555 , A61K2039/55566 , A61K2039/575 , A61K2039/6031 , A61K2039/6037 , A61K2039/6068 , A61K2039/6087 , A61K2039/62 , A61K2039/627 , A61K2039/70 , Y02A50/412
摘要： The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided comprising 10 or more capsular saccharides from different S. pneumoniae serotypes which are conjugated to a carrier protein, and comprising 3 or more different carrier proteins, wherein the composition comprises: serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT); serotype 18C capsular saccharide conjugated to tetanus toxoid (TT); serotype 1,4,5,6B,7F,9V,14 and 23F capsular saccharides conjugated to protein D from Haemophilus influenzae .

92. 发明公开

EP1670893A4 IMMUNOGENIC HIV COMPOSITIONS AND RELATED METHODS 审中-公开
标题翻译：免疫原性HIV组合物，并与连接方法
公开(公告)号：EP1670893A4
公开(公告)日：2008-09-03
申请号：EP04782469
申请日：2004-08-27
申请人： IMMUNE RESPONSE CORP INC
发明人： MOSS RONALD B
IPC分类号： A61K39/21 , A61K47/00 , A61P31/18 , C12N20060101 , C12Q1/70
CPC分类号： A61K39/21 , A61K39/00 , A61K39/12 , A61K2039/5252 , A61K2039/5254 , A61K2039/545 , A61K2039/55 , A61K2039/555 , A61K2039/55561 , A61K2039/55566 , A61K2039/57 , A61K2039/62 , A61K2039/627 , C07K14/005 , C12N2740/16222 , C12N2740/16234

93. 发明公开

EP1926496A1 PCV-2 VACCINE 有权
标题翻译： PCV-2 - VAKZINE
公开(公告)号：EP1926496A1
公开(公告)日：2008-06-04
申请号：EP06793347.3
申请日：2006-09-08
申请人： Intervet International B.V.
发明人： ROERINK, Frank , VAN WOENSEL, Peter
IPC分类号： A61K39/12 , A61P31/20
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5256 , A61K2039/545 , A61K2039/55 , A61K2039/552 , A61K2039/55511 , A61K2039/55566 , C12N7/00 , C12N15/86 , C12N2710/14143 , C12N2750/10034
摘要： The present invention relates to a vaccine against porcine drcovirus type 2 (PCV-)2 and a method for the manufacture of such a vaccine, for protecting piglets against PCV-2 infection. It has been found that a vaccine comprising at least 20 microgram/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2 is capable of eliciting a protective immune response against PCV-2 (and thus against PMWS) even when they have a relatively high titer of MDA against PCV-2. A vaccine according to the invention may contain a recombinant ORF-2 protein, wherein said recombinant protein is preferably produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.

94. 发明公开

EP1869208A1 ANTI-EGFR ANTIBODY THERAPY BASED ON AN INCREASED COPY NUMBER OF THE EGFR GENE IN TUMOR TISSUES 审中-公开
标题翻译： EGFR基因的肿瘤组织中的拷贝的抗EGFR抗体治疗的基础上增加NUMBER
公开(公告)号：EP1869208A1
公开(公告)日：2007-12-26
申请号：EP06724269.3
申请日：2006-04-12
申请人： Merck Patent GmbH
发明人： SIENA, Salvatore Ospedale Niguarda Ca'Granda , MORONI, Mauro Ospedale Niguarda Ca'Granda , MARRAPESE, Giovanna Ospedale Niguarda Ca'Granda , SARTORE-BIANCHI, Andrea Osped. Niguarda Ca'Granda , VERONESE, Silvio Ospedale Niguarda Ca'Granda , GAMBACORTA, Marcello Ospedale Niguarda Ca'Granda , BENVENUTI, Silvia University of Torino Medical School , DI NICOLANTONIO, Federica University of Torino Medical School , BARDELLI, Alberto University of Torino Medical School
IPC分类号： C12Q1/68 , C07K16/28
CPC分类号： A61K39/00 , A61K39/39541 , A61K2039/505 , A61K2039/55 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/73 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , A61K2300/00
摘要： The invention relates to an individualized and personalized diagnosis and therapy of cancer based on specific molecular alterations which occur in specific tumor tissue of specific tumor patient populations. The therapy and diagnostic is based on the findings that proliferation and tumor growth of specific EGFR bearing tumor tissue expressing an amplified EGFR gene copy number may be abolished by anti-EGFR antibodies, while other individual molecular alterations such as mutations occurring in tumor tissues are unaffected by the same anti-EGFR antibody treatment.

95. 发明授权

EP1420822B1 MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES 有权转让
标题翻译： MODIFIZIERTE VARIANTE DES VACCINIA ANKARA VIRUS ALS IMPFSTOFFFÜRNEUGEBORENE
公开(公告)号：EP1420822B1
公开(公告)日：2007-07-11
申请号：EP03732280.7
申请日：2003-04-16
申请人： Bavarian Nordic A/S
发明人： CHAPLIN, Paul , SUTER, Mark , ACKERMANN, Mathias , FRANCHINI, Marco , VOLLSTEDT, Sabine , HEFTI, Hans, Peter
IPC分类号： A61K39/285 , A61K39/245
CPC分类号： A61K39/285 , A61K39/12 , A61K39/245 , A61K2039/5254 , A61K2039/55 , A61K2039/58 , C12N7/00 , C12N2710/16634 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2710/24161 , Y02A50/386 , Y02A50/39 , Y02A50/394
摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.
摘要翻译：本发明涉及病毒用于制备用于疫苗接种或治疗新生儿或产前动物（包括人）的药物的用途，其中所述病毒能感染新生儿或产前动物（包括人）的细胞，但不能在新生儿或产前动物（包括人）中复制感染性后代病毒。病毒优选为改良的痘苗病毒安卡拉。特别地，本发明涉及新生儿针对与用于接种疫苗的病毒相同的病毒组的病毒感染的接种。此外，本发明涉及新生儿针对选自外源抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。本发明还涉及如上定义的病毒的使用以增加激活树突细胞或其前体细胞的因子水平和/或增加树突状细胞或其前体细胞的数量和/或增加生产和/或细胞干扰素（IFN）或IL-12的含量。

96. 发明授权

EP1298139B1 Avian herpes virus-based recombinant infectious bursal disease vaccine 有权
标题翻译：成立于传染性Bursalkrankheit疱疹病毒重组疫苗
公开(公告)号：EP1298139B1
公开(公告)日：2007-05-02
申请号：EP02021736.0
申请日：2002-09-25
申请人： ZEON CORPORATION
发明人： Sato, Takanori , Tsuzaki, Yoshinari , Esaki, Motoyuki , Dorsey, M. Kristi
IPC分类号： C07K14/08 , A61K39/12 , C12N15/86 , C12N15/38
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5256 , A61K2039/55 , A61K2039/552 , C12N2710/16321 , C12N2720/10034 , Y10S424/816
摘要： The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype I strains. The present invention further provides an avian recombinant herpesvirus comprised of the VP2 gene, of which the backbone virus is a Marek's disease vaccine strain, such as herpesvirus of turkeys. A poultry vaccine including the avian herpes recombinant virus described in the present invention can induce in chickens protective immunity against a variety of different subtypes of IBDV.

97. 发明公开

EP1660664A1 POXVIRUS VECTOR ENCODING PROSTATE SPECIFIC ANTIGENS FOR TREATMENT OF PROSTATE CANCER 审中-公开
标题翻译：前列腺特异性抗原编码痘病毒载体的前列腺癌的治疗
公开(公告)号：EP1660664A1
公开(公告)日：2006-05-31
申请号：EP04761166.0
申请日：2004-08-20
申请人： Virax Development Pty Ltd.
发明人： BROWN, Michael, Paul , HOWLEY, Paul, Michael
IPC分类号： C12N15/863 , A61K39/00 , A61P35/00 , C12N15/12
CPC分类号： C12N9/16 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , A61K2039/55 , A61K2039/55533 , C07K14/4748 , C07K16/3076 , C12N7/00 , C12N15/86 , C12N2710/24032 , C12N2710/24043 , C12N2710/24143 , A61K2300/00
摘要： A genetic vaccine construct comprising a poxvirus vector which incorporates and, on administration to a subject, expresses in a cell of said subject a sequence of nucleotides encoding a prostate-specific polypeptide, wherein said poxvirus vector does not productively infect said subject. The genetic vaccine construct is for treatment of prostate cancer. The prostate specific polypeptide is preferably rat prostatic acid phosphatase, and is preferably xenogenic to the subject. The proxvirus vector is an avipox virus vector, preferably a fowl poxvirus vector. The genetic vaccine construct may also encode for one or more cytokines.

98. 发明公开

EP1490105A4 MULTIPLE AND MULTIVALENT DNA VACCINES IN OVO 有权
标题翻译：多个和多VALENTE DNA疫苗的OVO
公开(公告)号：EP1490105A4
公开(公告)日：2006-04-19
申请号：EP03744203
申请日：2003-03-06
申请人： SCHWEITZER CHEMICAL CORP USA
发明人： KUO TSUN-YUNG
IPC分类号： C12N15/09 , A61K35/76 , A61K39/00 , A61K39/295 , A61K48/00 , A61P31/12 , C07K14/055 , C07K14/08 , C07K14/125 , C07K14/165 , A61K39/255 , A01N65/00 , C07H21/04 , C12N7/00 , C12N15/00 , C12N15/66 , C12P19/34
CPC分类号： C07K14/005 , A61K2039/53 , A61K2039/54 , A61K2039/55 , A61K2039/70 , C12N2710/16322 , C12N2720/10022 , C12N2760/18122 , C12N2770/20022

99. 发明公开

EP1626694A2 VACCINE ACCELERATOR FACTOR (VAF) FOR IMPROVEMENT OF VACCINATIONS IN POULTRY 审中-公开
标题翻译：疫苗加速因子（IBF），可改善家禽疫苗接种
公开(公告)号：EP1626694A2
公开(公告)日：2006-02-22
申请号：EP04751354.4
申请日：2004-05-06
申请人： Schweitzer Chemical Corporation Ltd.
发明人： KUO, Tsun-Yung
IPC分类号： A61K6/00
CPC分类号： A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55 , A61K2039/552 , A61K2039/70 , C07K14/005 , C12N2710/16322 , C12N2710/16334 , C12N2720/10022 , C12N2720/10034 , C12N2760/18122 , C12N2760/18134 , C12N2770/20022 , C12N2770/20034
摘要： The present invention provides a vaccine accelerator factor (VAF) which is an in ovo nucleotide immuno-stimulant. The VAF contains one or more DNA constructs, each having a DNA molecule and a vector. Each of the DNA molecule contains one or more genes or gene fragments, each encoding an antigenic peptide of an avian virus. The VAF is preferably administered to the amniotic fluid of an egg after being fertilized for about 17-19 days. The VAF can be co-administered with a viral vaccine containing one or more attenuated or inactive avian viruses. Alternatively, the VAF can be administered prior to the administration of the viral vaccine, which is administered at hatch or post-hatch. The VAF stimulates and accelerate a protective immune response of a viral vaccine.

100. 发明公开

EP1599128A2 METHODS OF TREATING DISEASE BY TRANSPLANTATION OF DEVELOPING ALLOGENEIC OR XENOGENEIC ORGANS OR TISSUES 审中-公开
标题翻译：方法治疗疾病的BY移植异体开发或异种器官或组织
公开(公告)号：EP1599128A2
公开(公告)日：2005-11-30
申请号：EP04717207.7
申请日：2004-03-04
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.
发明人： Reisner, Yair , Dekel, Benjamin
IPC分类号： A61B1/00
CPC分类号： A61K39/001 , A61K35/12 , A61K38/1774 , A61K2039/55 , C12N5/0648 , C12N5/065 , C12N5/0651 , C12N5/0657 , C12N5/067 , C12N5/0676 , C12N5/0686 , G01N2800/245
摘要： The present convention concerns the use of a pancreatic organ or tissue graft for the manufacture of a medicament identified for treating a pancreatic disorder associated with a pathological organ or tissue physiology or morphology, the pancreatic organ or tissue graft selected not substantially expressing or presenting at least one molecule capable of stimulating or enhancing an immune response in a subject and wherein the pancreatic organ or tissue graft is non-human.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式